abemaciclib,ribociclib
eli lilly,novartis
['verzenio', 'kisqali', 'breast', 'novartis', ' lilly']
novartis' kisqali has been trailing behind its cdk4/6 competitors an approval in early breast cancer could give it a big boost. but in lower-risk groups (which could set kisqali apart from lilly's verzenio), data are mixed. #asco23 : 
reporting on drugs and biotechs @endpts • email me: lwu@endpointsnews.com • ✌️